News Sentiment

IBIO sentiment intelligence

iBio, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.51 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

74/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-10.1% over one week, -10.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 74/100 classification
One-week reaction -10.1% Price reacting lower
Trend fit Trend inactive -10.7% over four weeks
Fair value -40.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 27
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 7
simplywall.st 3
MarketBeat 2
Quiver Quantitative 2
Insider Monkey 2
Stocktwits 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Earnings 17
Market update 13
Analyst action 8
Balance sheet 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 42
MarketBeat Direct company coverage

iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages

iBio, Inc. (NASDAQ:IBIO) has received a consensus "Buy" rating from eight brokerages, with an average 12-month price target of $5.00, despite a recent share price of $1.44. Analyst actions have been mixed, with some maintaining bullish ratings while others downgraded to "sell." T

Tone
Positive 64/100
Event
Analyst action
Published
15 Jul 2026 08:12
Source
MarketBeat
MarketBeat Direct company coverage

iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded iBio (NASDAQ:IBIO) from a "hold" to a "sell" rating, though other analysts still predominantly rate the stock as "buy" with a consensus price target of $5.00. The company's stock remained flat at $1.51 on Friday, significantly below its 52-week high, an

Tone
Negative 37/100
Event
Analyst action
Published
12 Jul 2026 17:40
Source
MarketBeat
Sahm Direct company coverage

We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth

iBio (NASDAQ:IBIO), a biotech company that currently does not generate significant operating revenue, had a cash runway of about 3.4 years as of March 2026, with US$75m in cash and no debt. The company's cash burn increased by 41% in the last year to US$22m, indicating increased

Tone
Neutral 50/100
Event
Balance sheet
Published
09 Jul 2026 17:09
Source
Sahm
TradingView Direct company coverage

Price to sales forward of iBio, Inc. – NASDAQ:IBIO

This article provides only the title "Price to sales forward of iBio, Inc. – NASDAQ:IBIO" and a table header "Period Value Change Change %" within the content. There is no accompanying financial data or analysis for iBio, Inc.'s price to sales forward metric. The majority of the

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 19:39
Source
TradingView
Finviz Direct company coverage

IBIO - iBio Inc Latest SEC Filings

This article provides the latest SEC filing information for iBio Inc (IBIO), including key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $1.68, down 4.00%, with a market cap of $83.

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 09:13
Source
Finviz
Stock Titan Direct company coverage

iBio (NASDAQ: IBIO) obesity antibody cuts Activin E and spares lean mass

iBio (NASDAQ: IBIO) announced positive preclinical results for its IBIO-610 antibody, targeting Activin E for obesity and related diseases. In obese non-human primates, a single dose of IBIO-610 reduced active Activin E by up to 98% for eight weeks and, when combined with semaglu

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 11:40
Source
Stock Titan
GlobeNewswire Direct company coverage

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete

iBio, Inc. announced new preclinical data for its IBIO-610 antibody candidate, showing that a single dose achieved near-complete inhibition of active Activin E for eight weeks in obese non-human primates. When combined with semaglutide, IBIO-610 significantly increased visceral a

Tone
Positive 95/100
Event
Market update
Published
01 Jul 2026 10:40
Source
GlobeNewswire
www.marketscreener.com Direct company coverage

IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Index

iBio, Inc. (NasdaqCM: IBIO) has been added to the Russell Microcap Index, as announced on June 28, 2026. This inclusion reflects the company's standing in the financial markets. iBio is a biotechnology company focused on developing advanced biopharmaceuticals for various diseases

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 16:12
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of iBio, Inc. – NASDAQ:IBIO

This article provides financial information for iBio, Inc. (NASDAQ: IBIO), specifically focusing on its enterprise value to EBIT forward metric. It appears to be a stub or a placeholder page from TradingView, indicating where this financial data would typically be displayed.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of iBio, Inc. – NASDAQ:IBIO

This article provides a brief overview of iBio, Inc. (NASDAQ: IBIO) with a focus on its price-to-book forward ratio. It appears to be a stub or a data-focused entry from TradingView, displaying financial metrics rather than an in-depth analysis. The content emphasizes financial d

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of iBio, Inc. – NASDAQ:IBIO

This article provides financial information for iBio, Inc. (NASDAQ: IBIO) focusing on its enterprise value to revenue forward. The content is presented within the TradingView platform, offering various financial metrics and market data for the company.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

0JV0 Forecast — Price Target — Prediction for 2027

This article provides a forecast for iBio, Inc. (0JV0) stock, including analyst price targets and ratings. It details the company's past financial performance, future earnings and revenue expectations, and addresses frequently asked questions about its stock ticker, highest/lowes

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:10
Source
TradingView
TradingKey Direct company coverage

iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of iBio Inc.'s (IBIO) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years. However, it details several merger-related stock reverse splits that occurred in October 2023

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 06:09
Source
TradingKey
富途牛牛 Direct company coverage

Raymond James Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $5

Raymond James has initiated coverage on IBio Inc (IBIO.US) with a "Buy" rating. The firm has set a target price of $5 for the company's stock. This indicates a positive outlook from Raymond James regarding IBio Inc's future performance.

Tone
Positive 77/100
Event
Analyst action
Published
15 Jun 2026 19:10
Source
富途牛牛
Insider Monkey Direct company coverage

Could iBio (IBIO) Be an Underrated Obesity Stock?

iBio, Inc. (NASDAQ:IBIO) is gaining attention as a potentially underrated obesity stock, with Raymond James initiating coverage with an Outperform rating and a $5 price target due to its emerging obesity-focused pipeline. The company recently dosed its first participant in a Phas

Tone
Positive 73/100
Event
Analyst action
Published
11 Jun 2026 20:37
Source
Insider Monkey
Insider Monkey Direct company coverage

5 Under-the-Radar AI Stocks to Buy in 2026

This article identifies five under-the-radar AI stocks for investors to consider in 2026, including iBio, Inc., Veritone, Inc., Innodata Inc., Mitek Systems, Inc., and Lantronix, Inc. Each company is discussed with recent financial or operational updates, along with analyst opini

Tone
Positive 74/100
Event
Analyst action
Published
11 Jun 2026 16:33
Source
Insider Monkey